GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (OSL:ULTI) » Definitions » Loans Receivable

Ultimovacs ASA (OSL:ULTI) Loans Receivable : kr0.00 Mil (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Ultimovacs ASA Loans Receivable?

Ultimovacs ASA's Loans Receivable for the quarter that ended in Dec. 2023 was kr0.00 Mil.


Ultimovacs ASA Loans Receivable Historical Data

The historical data trend for Ultimovacs ASA's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultimovacs ASA Loans Receivable Chart

Ultimovacs ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only - - - - -

Ultimovacs ASA Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Ultimovacs ASA Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Ultimovacs ASA Loans Receivable Related Terms

Thank you for viewing the detailed overview of Ultimovacs ASA's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Ultimovacs ASA (OSL:ULTI) Business Description

Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, 0379
Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.